FGF19 and metabolic dysfunction-associated steatotic liver disease: Furthermore, the circulating FGF-19 concentration is reduced in patients with NAFLD, suggesting that dysregulated FGF-19 expression might contribute to the pathogenesis of NAFLD [28,69].